KAER Biotherapeutics Corporation

12:15 PM - 12:30 PM (EDT), Wednesday, June 7, 2023 ・ Session Room 103
KAER focuses on high dose delivery of aerosolized drugs for serious and life-threatening respiratory disorders within clinical settings such as ICU, PICU, surgical suites and emergency rooms. Inadequate deposition of aerosolized therapeutics in the distal lungs is associated with treatment failure. The 40% mortality rate of patients from respiratory distress is unacceptable. To address these issues, KAER developed two novel medical devices. AeroPulsR and SUPRAER enable liquids containing high concentrations of small and oligomeric molecules to be aerosolized and delivered as either aqueous or solid-phase aerosols, respectively. These devices are suitable for deposition in the distal lungs of patients of all ages, as well as for animal health applications. Albeit acute respiratory distress affects patients of all ages, KAER’s first clinical study focuses on the delivery of surfactant aerosol to pediatric patients aged 6-12 years with respiratory distress resultant from pneumonia.
Not Provided
Not Provided
Company Type:
Not Provided
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
AeroPulsR, Aerosol delivery of high dose rates of small and large oligomer molecules for treatment in pediatric and adult patients with respiratory distress
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
KAER Biotherapeutics